Rujukan Profilaksis prapendedahan

  1. ↑ "Pre-Exposure Prophylaxis". HIV.gov. 2019-12-03. Dicapai pada 2020-08-03.
  2. 1 2 3 4 5 6 US Public Health Service. "Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014" (PDF). Centers for Disease Control and Prevention (CDC). Diarkibkan daripada yang asal (PDF) pada 11 April 2018. Dicapai pada 15 Disember 2017.
  3. ↑ "Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV". Centers for Disease Control and Prevention (CDC). 2019-11-12. Diarkibkan daripada yang asal pada 10 Disember 2019. Dicapai pada 9 Disember 2019.
  4. 1 2 "FDA approves the second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic" (Siaran akhbar). 3 Oktober 2019. Diarkibkan daripada yang asal pada 10 Oktober 2019. Dicapai pada 10 Oktober 2019. Rencana ini mengandungi teks dari suatu penerbitan yang kini berada dalam domain awam:
  5. 1 2 "FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention". U.S. Food and Drug Administration. 20 Disember 2021. Dicapai pada 20 April 2022.
  6. ↑ "National Policies and Guidelines for PrEP". PrEP Watch. Dicapai pada 5 Disember 2017.
  7. ↑ "HIV Preexposure Prophylaxis: A Review". JAMA. 319 (12): 1261–1268. March 2018. doi:10.1001/jama.2018.1917. PMID 29584848.
  8. ↑ "Pre-Exposure Prophylaxis (PrEP) | HIV Risk and Prevention | HIV/AIDS | CDC". www.cdc.gov. 2020-06-04. Dicapai pada 2020-07-30.
  9. ↑ Ryan, Benjamin (16 Februari 2017). "PrEP Fails in a Third Man, But This Time HIV Drug Resistance Is Not to Blame". Poz. Dicapai pada 15 Disember 2017.
  10. ↑ "Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network". Annals of Internal Medicine. 134 (1): 25–9. Januari 2001. doi:10.7326/0003-4819-134-1-200101020-00010. PMID 11187417. Unknown parameter |displayauthors= ignored (bantuan)
  11. ↑ "Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update Clinical Practice Guideline" (PDF). Centers for Disease Control and Prevention.
  12. ↑ "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. June 2019. doi:10.1001/jama.2019.2591. PMID 31184746. Unknown parameter |displayauthors= ignored (bantuan)
  13. ↑ "Recent advances in pre-exposure prophylaxis for HIV". BMJ. 359: j5011. December 2017. doi:10.1136/bmj.j5011. PMC 6020995. PMID 29229609.
  14. ↑ What's the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: Update to WHO's recommendation on oral PrEP. Geneva: World Health Organization; 2019 (WHO/CDS/HIV/19.8). Licence: CC BY-NC-SA 3.0 IGO.
  15. ↑ "Preventing HIV During Pregnancy And Breastfeeding in the Context of PrEP". WHO Technical Brief: 16. 2017.
  16. 1 2 "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection". World Health Organization.
  17. ↑ "Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions". Drugs. 79 (12): 1263–1276. August 2019. doi:10.1007/s40265-019-01143-8. PMID 31309457.
  18. ↑ "HIV preexposure prophylaxis: new data and potential use". Topics in Antiviral Medicine. 19 (5): 181–5. December 2011. PMC 6148898. PMID 22298887.
  19. ↑ "Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation". Journal of Acquired Immune Deficiency Syndromes. 73 (5): 540–546. December 2016. doi:10.1097/QAI.0000000000001129. PMC 5424697. PMID 27851714. Unknown parameter |displayauthors= ignored (bantuan)
  20. 1 2 "Truvada- emtricitabine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Dicapai pada 9 Disember 2019.
  21. ↑ "HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health". AIDS. 34 (5): 699–706. April 2020. doi:10.1097/QAD.0000000000002456. PMC 7071971. PMID 31794523. Unknown parameter |displayauthors= ignored (bantuan)
  22. ↑ "New research at CROI 2016: How PrEP changes kidney function". San Francisco AIDS Foundation. 2016-03-08. Dicapai pada 2020-08-03.
  23. ↑ "Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns". Drug Safety. 40 (4): 273–283. April 2017. doi:10.1007/s40264-017-0505-6. PMC 5362649. PMID 28130774.
  24. ↑ Kenslea, Ged (11 April 2019). "41 HIV and PrEP Patients File California Personal Injury Lawsuit Over Gilead's TDF-Based Drugs". AIDS Healthcare Foundation (AHF). Dicapai pada 9 Disember 2019.
  25. ↑ "AHF Calls on Gilead to Set Up $10 Billion Fund for Victims Harmed by its TDF-based Drugs". AIDS Healthcare Foundation (AHF). 16 Julai 2019. Dicapai pada 10 Disember 2019.
  26. ↑ Petersen, Melody (29 May 2016). "A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner". Los Angeles Times. Dicapai pada 9 Disember 2019.
  27. ↑ "Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss". Biochemical and Biophysical Research Communications. 394 (1): 48–53. March 2010. doi:10.1016/j.bbrc.2010.02.080. PMC 2847063. PMID 20171173.
  28. 1 2 3 "Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana". PLOS ONE. 9 (3): e90111. 2014-03-13. Bibcode:2014PLoSO...990111K. doi:10.1371/journal.pone.0090111. PMC 3953113. PMID 24625530. Unknown parameter |displayauthors= ignored (bantuan)
  29. ↑ "Changes to Your Face and Body (Lipodystrophy & Wasting)". Poz. Dicapai pada 2018-02-16.
  30. ↑ "PrEP does not raise lipids or alter body fat, safety study finds". Dicapai pada 2018-02-16.
  31. ↑ "Truvada as HIV PrEP not associated with net fat increase". www.healio.com. Dicapai pada 2018-02-16.
  32. ↑ "Resource: Side-by-side comparison: Truvada and Descovy for PrEP". San Francisco AIDS Foundation. Dicapai pada 2020-08-03.
  33. ↑ Gilead. "U.S. Food and Drug Administration Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV". Gilead. Dicapai pada 15 Disember 2017.
  34. ↑ "Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects" (PDF). Pertubuhan Kesihatan Sedunia (WHO). July 2012.
  35. ↑ "Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations, 2014" (PDF). Pertubuhan Kesihatan Sedunia (WHO). July 2014.
  36. ↑ "WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP)" (PDF). Pertubuhan Kesihatan Sedunia (WHO). November 2015. Dicapai pada 18 Disember 2015.
  37. ↑ "HIV prevention drug Truvada to be publicly funded in New Zealand". TVNZ. Dicapai pada 7 Februari 2018.
  38. ↑ "PrEP". Australian Federation of AIDS Organisations. Dicapai pada 2020-07-31.
  39. ↑ "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17". The Lancet. HIV. 5 (8): e448–e456. August 2018. doi:10.1016/S2352-3018(18)30072-9. PMID 29885813. Unknown parameter |displayauthors= ignored (bantuan)
  40. ↑ Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., … Guanira, J. V. (2012). Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Science Translational Medicine, 4(151), 151ra125–151ra125. doi:10.1126/scitranslmed.3004006